Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2018

View Archived Issues

AhR antagonist PX-A24590 shows efficacy in pancreatic tumor model

Tavalisse becomes available in the U.S.

Xalkori receives FDA breakthrough therapy designation in two new indications

Clinical trial authorization received in U.K. to initiate phase I study with OLX-10010

Pivotal phase III of chidamide in combination with exemestane reaches primary endpoint

ITGA3 suggested as a therapeutic target in bladder cancer

European Commission grants authorization to Rubraca for recurrent ovarian cancer

FDA accepts NDA and grants priority review status for Firdapse

FDA accepts NDA for larotrectinib and grants priority review

U.S. researchers patent ITGA4 antagonists

Auckland Uniservices divulges CSF1R inhibitors

Russian investigators patent ciprofloxacin derivatives

New nicotinic alpha7 receptor PAMs presented by Merck & Co.

Genentech and Roche patent RORC ligands

EMA validates MAA for Inbrija

Galafold launched in Japan for Fabry disease

HyLeukin-7 begins U.S. trial in brain cancer

FDA accepts Cabometyx sNDA for previously treated HCC

miR-126 and miR-223 found as potential biomarkers of cardiac sarcoidosis

Antitumor efficacy seen with HERA-GITRL fusion protein from Apogenix

Nur77-deficient mice show altered dendritic cell functioning

FDA approves Imvexxy to treat moderate to severe dyspareunia due to menopause

Atox initiates phase II trial of reltecimod in acute kidney injury

FDA grants priority review to Sage's NDA for intravenous brexanolone for postpartum depression

DSMB clears phase II trial of AG-013 for oral mucositis to continue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...